Retinal Vein Occlusion

Overview of branch retinal vein occlusion and central retinal vein occlusion.

What is a Retinal Vein Occlusion?

Arteries bring blood to the eye and veins bring blood back to the heart. While arteries have tough walls which usually become harder with age, veins have thin walls which remain pliant and soft throughout life. Because of the anatomy of the eye, the retinal veins are prone to occlusion. There are two main locations where retinal veins are occluded. One is at the crossing of a retinal arteriole and branch retinal vein. An occlusion at a crossing of a branch retinal arteriole and branch retinal vein causes a branch retinal vein occlusion. The second is at the main trunk of the retinal vein where it leaves the eye through the optic nerve. An occlusion at the main trunk of the retinal vein causes a central retinal vein occlusion. The picture shows a photo with dilated veins and retinal hemorrhages from a fresh central retinal vein occlusion.

What is a Branch Retinal Vein Occlusion?

A branch retinal vein occlusion occurs when, because of hardening of the arteries, a branch retinal artery compresses a branch retinal vein causing blockage of the vein and decreased circulation in the distribution of that branch retinal vein. (see image) [note: the branch arteries are really arteriols and the branch veins are really veinules] There are several possible treatments for branch retinal vein occlusion including intravitreal injections, laser, and even surgery. Patients with BRVO lose vision for several reasons: poor circulation, hemorrhage and macular edema (swelling). There is no treatment, at the moment, to increase circulation or to remove hemorrhage. The macular edema, however, does respond well to intravitreal injections with Lucentis, Avastin, or steroids.

Read more

What is a Central Retinal Vein Occlusion?

The inner layers of the retina receive their blood supply from the central retinal artery. The blood returns to the heart through the central retinal vein. Both vessels enter the eye through a small opening in the middle of the optic nerve. Either because this opening shrinks or because the artery hardens or because of circulations problems, the central retinal vein can become partially or completely occluded. When a patient develops a central retinal vein occlusion (CRVO), they lose some or most of their central vision. The retinal veins dilate and their are retinal hemorrhages. Patients often develop swelling of the central retina-cystoid macular edema--causing some of the vision loss. Without treatments, 25% of eyes improve, 50% stabilize, and 25% worsen. Monthly examinations of pateints with CRVO for less than six months are very important. Some patients with CRVO and very bad circulation, develop a severe type of glaucoma. In this situation, the eye becomes red and painful and without treatment, total visual loss can occur rapidly. If an examining doctor sees early signs that this complication may occur, then laser treatment can sometimes protect the eye. Once the pressure rise occurs, surgery can be helpful.

Read more

Retinal Vein Occlusion NEWS

Below are current articles from a Google News Feed on Retinal Vein Occlusion

Focus on Eyes: Vision loss and retinal vein occlusion  Florida Today

When a retinal vein is blocked, it can lead to severe loss of vision.

Global Retinal Vein Occlusion (RVO) Treatment Market (2019-2023): Projected to Register a CAGR of 9.4% - ResearchAndMarkets.com  Business Wire

DUBLIN--(BUSINESS WIRE)--The "Global Retinal Vein Occlusion Treatment Market 2019-2023" report has been added to ResearchAndMarkets.com's offering.

Post-marketing surveillance study of the safety of dexamethasone intra | OPTH  Dove Medical Press

Post-marketing surveillance study of the safety of dexamethasone intravitreal implant in patients with retinal vein occlusion or noninfectious posterior segment ...

Increase in choroidal thickness seen after CPAP therapy  Healio

Patients with obstructive sleep apnea syndrome who underwent continuous positive airway pressure therapy experienced an increase in choroidal thickness ...

Europe's Luxturna approval tops November retina news  Healio

The European Commission's approval of Luxturna for inherited retinal disease was the most-read retina-related article on Healio.com/OSN in November.

Dr. Mali's top 5 stories in ophthalmology for 2018  Ophthalmology Times

It's that time of the year again when I reflect on such an exciting and dynamic year in ophthalmology! Here are my top 5 most significant stories in ophthalmology ...

Global Retinal Vein Occlusion Therapeutics Market 2018 – Acucela Inc, Addmedica SAS, Aerpio Therapeutics Inc, Annexin Pharmaceuticals AB, Chengdu Kanghong Pharmaceuticals Group Co Ltd  Daily Industry Updates

The Global Retinal Vein Occlusion Therapeutics Market provides an in-depth look and share detailed information about the key factors influencing the growth of ...

High-Dose ITVA Found Considered Safe, Cost-Effective Alternative to Anti-VEGF  MD Magazine

A new study finds high-dose intravitreal triamcinolone acetonide is a safe alternative to anti-vascular endothelial growth factor, a finding that is welcome news for ...

Safety of high-dose intravitreal triamcinolone acetonide as low-cost a | OPTH  Dove Medical Press

Hammouda Hamdy Ghoraba,1,2 Mahmoud Leila,3 Sameh Mohamed Elgouhary,4 Emad Eldin Mohamed Elgemai,2,5 Haithem Mamon Abdelfattah,2,6 Hashem ...

Daily Research News Online no. 27214 - Ipsos Launches Ophthalmology Monitor  Daily Research News Online

Ipsos has launched a Global Ophthalmology Therapy Monitor - the latest addition to its Syndicated Real World Evidence Portfolio - in the big five EU markets ...

2018-2023 Global Virtual Prototype Market Overview and Market Application  The Flatland Post

The Global Global Virtual Prototype Market 2018 by Manufacturers, Countries, Type and Application, Forecast to 2023: Virtual Prototype Market Report ...

CF Patients at Greater Risk for Occlusions in Retinal Vessels, Case Report Suggests  Cystic Fibrosis News Today

A case report suggests that cystic fibrosis patients have a higher risk of retinal vein occlusions as a complication of their pro-inflammatory status.

Regeneron (REGN) Rides on Eylea and Dupixent's Performance  Zacks.com

Solid performance of approved drugs like Eylea and Dupixent along with an encouraging pipeline progress improve Regeneron's (REGN) market position.

KOD Catches Eyes, MRNS On Watch, Mark Your Calendar For AQST  Nasdaq

Gained 22.37% to close Thursday's trading at $9.30. The Company went public on the Nasdaq Global Market on October 4, 2018, offering its shares at a.

First Republic Investment Management Inc. Reduces Stake in Regeneron Pharmaceuticals Inc (REGN)  Fairfield Current

First Republic Investment Management Inc. decreased its stake in shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 9.6% during the 3rd quarter, ...

Global Retinal Vein Occlusion Therapeutics Market Insights 2015-2025: Acucela Inc, Addmedica SAS, Aerpio Therapeutics Inc  The Massage Advancer

The global “Retinal Vein Occlusion Therapeutics market” research report portrays a deep analysis of the global Retinal Vein Occlusion Therapeutics market.

Global Retinal Vein Occlusion Therapeutics Market Insights 2018-2024: Acucela Inc, Addmedica SAS, Aerpio Therapeutics Inc  Anglophone Tribune

The market report, titled “Retinal Vein Occlusion Therapeutics Market“, is a broad research dependent on Retinal Vein Occlusion Therapeutics market, which ...

Why Regeneron Pharmaceuticals Inc (NASDAQ:REGN) Could be Ready to Star in the Speculative Spotlight  FDA Headlines

Dec 7, 2018 | Business. Why Regeneron Pharmaceuticals Inc (NASDAQ:REGN) Could be Ready to Star in the. Regeneron Pharmaceuticals Inc ...

Mix of old and new sees ophthalmology updates! Flourish  Insight News

A unique formula and talented line-up of presenters has seen Ophthalmology Updates! go from strength-to-strength during its short history. In part two of his ...

Retinal Vein Occlusion Therapeutics Market Application Analysis, Analysis, Market Size, Regional Outlook, Competitive Strategies and Forecasts, 2018 To 2025 : EMEA (Europe, Middle East and Africa)  Leading Journal

The entire all around give a report of the Retinal Vein Occlusion Therapeutics Market industry, and the comprehensive report revolve around the current ...

Phase 3 data confirms safety, efficacy of filgotinib for RA  Healio

CHICAGO – Filgotinib improved the signs and symptoms of rheumatoid arthritis among previously treated patients with highly active disease, according to ...

KOD For The Long Haul, GMDA Turning Heads, TNDM Jumps On Analyst Upgrade  Nasdaq

The Company went public on the Nasdaq Global Market on October 4, 2018, offering its shares at a price of $10.00 each. The net loss for the third.

Reviewing Akebia Therapeutics (AKBA) and OHR Pharmaceutical (OHRP)  Fairfield Current

Akebia Therapeutics (NASDAQ:AKBA) and OHR Pharmaceutical (NASDAQ:OHRP) are both small-cap medical companies, but which is the better investment?

Clearside Bio's Xipere flunks late-stage retinal vein occlusion study; shares down 27% premarket  Seeking Alpha

Thinly traded micro cap Clearside Biomedical (CLSD) is down 27% premarket on light volume in response to its announcement that a Phase 3 clinical trial, SA.

Anti-VEGF treatment of macular edema associated with retinal vein occl | OPTH  Dove Medical Press

Anti-VEGF treatment of macular edema associated with retinal vein occlusion: patterns of use and effectiveness in clinical practice (ECHO study report 2) J ...

Specialist shares key messages of Euretina guidelines for management of RVO  Healio

VIENNA — A thorough ocular examination, early treatment and a timely switch of nonresponders are key for successful management of retinal vein occlusion, ...

Retinal Vein Occlusion Market Rising Demand Seen in Healthcare at a CAGR of 11.2% by 2023 | By Types Branch Retinal Artery Occlusion, Central Retinal Vein Occlusion – Says MRFR |  Medgadget

Market Research Future published a research report on “Global Retinal Vein Occlusion Market” to track and analyses developments which are competitive in.

Charles Bonnet Syndrome Signs and Symptoms  News-Medical.net

Charles Bonnet Syndrome (CBS) is a medical condition experienced by people who have deteriorating eyesight wherein they see things or objects that are not ...

Retinal Vein Occlusion (RVO) Market to Observe Strong Growth at a CAGR of 11.2% till 2023 | by MRFR |  Medgadget

Market Research Future (MRFR)'s study reveals that the “Global Retinal Vein Occlusion Market”, the report offer detailed Analysis about the Top Trends and.

Morphological Implications of Vascular Structures Not Visualized on Optical Coherence Tomography Angiography in Retinal Vein Occlusion  Healio

Ophthalmic Surgery, Lasers and Imaging Retina | BACKGROUND AND OBJECTIVE:Advanced retinal imaging can improve understanding of retinal vein ...

Global Retinal Vein Occlusion Market Epidemiology Research Report 2018  TokensJournal

Retinal Vein Occlusion- Epidemiology market gives comprehensive study of the important industry players has been done to offer understandings into their ...

Better Buy: Vertex Pharmaceuticals vs. Regeneron Pharmaceuticals  The Motley Fool

Ascending and descending? That might be how some investors view Vertex Pharmaceuticals (NASDAQ:VRTX) and Regeneron Pharmaceuticals ...

Charles Bonnet Syndrome Management  News-Medical.net

Charles Bonnet Syndrome (CBS) is an ophthalmologic condition present in about one-third of persons with visual impairment. Patients with CBS experience ...

Head to Head Survey: Clearside Biomedical (CLSD) vs. KemPharm (KMPH)  Fairfield Current

Clearside Biomedical (NASDAQ:CLSD) and KemPharm (NASDAQ:KMPH) are both small-cap medical companies, but which is the superior investment? We will ...

Retinal Vein Occlusion Market Size and Trend by Branch and Central Retinal Vein Occlusion Type, Etc. Types and Forecast to 2023 |  Medgadget

Glaucoma is a condition where the eye pressure causes damage to the optic nerve. The increasing number of patients with glaucoma is leading the retinal vein ...

Effect of intravitreal ranibizumab on serous retinal detachment in bra | OPTH  Dove Medical Press

Effect of intravitreal ranibizumab on serous retinal detachment in branch retinal vein occlusion Emine Dogan,1 Ozkan Sever,2 Burcin Köklü Çakir,1 Erkan Celik1 ...

Ophthalmic Drugs Market 2018 Receives a Rapid Boost in Economy Due to High Emerging Demands with CAGR of 6.0% by Forecast to 2023 - Press Release  Digital Journal

Market Research Future with their unique quality of simplifying the market research study, announces a deep study report on “Ophthalmic Drugs Market ...

Ozurdex for retinal vein occlusion available in China  Healio

Ozurdex is now available in China for the treatment of adult patients with macular edema secondary to retinal vein occlusion, Allergan announced in a press ...

Interface Biologics Announces New VP, Business Development  Associated Press

TORONTO, Dec. 04, 2018 (GLOBE NEWSWIRE) -- Interface Biologics Inc. (“IBI”), a privately held, commercial stage developer of innovative material science ...

Pro-Charming Shoppes Inc Big Money Sentiment Runs Low in 2018 Q3, Currently at 1.11  The EN Bulletin

“Big money sentiment for Charming Shoppes Inc (NASDAQ:CHRS) in Q3 2018 decreased to 1.11, SEC.gov filings reveal. That's down -1.17, from 2018Q2's 2.28 ...

IOP spikes more likely after treatment in certain patients  Healio

Mild to moderate IOP spikes were seen after multiple injections of Ozurdex for treatment of uveitis, diabetic macular edema and retinal vein occlusion, but ...

Global Retinal Vein Occlusion Therapeutics Market Base Distribution, Sales Area, Product Types by Players, Consumption by Countries, Drivers, Challenges and Trends, Forecast 2023.  MSR Sports Desk

Retinal Vein Occlusion Therapeutics Market report on Global Retinal Vein Occlusion Therapeutics Market Analysis 2012-2017 and Forecast 2018-2023.

Global Retinal Vein Occlusion Therapeutics Market 2018- Trade Growth Factors, Rating Analysis, and Key Drivers- 2023  Browse Live News

Global Retinal Vein Occlusion Therapeutics Market Research Report has incorporated an absolute analysis of Retinal Vein Occlusion Therapeutics industry ...

Regeneron Pharmaceuticals Inc (REGN) Shares Bought by MML Investors Services LLC  Fairfield Current

MML Investors Services LLC grew its holdings in shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 25.8% in the 3rd quarter, according to its most ...

Clearside Biomedical Announces Completion of Patient Enrollment in First of Two Phase 3 Clinical Trials of CLS-TA in Retinal Vein Occlusion  GlobeNewswire

ALPHARETTA, Ga., June 13, 2018 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing ...

Clearside Biomedical Provides Update on Two Phase 3 Clinical Trials of CLS-TA in Retinal Vein Occlusion  GlobeNewswire

ALPHARETTA, Ga., March 06, 2018 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage biopharmaceutical company developing ...

Commonwealth of Pennsylvania Public School Empls Retrmt SYS Has $2.57 Million Holdings in Regeneron Pharmaceuticals Inc (NASDAQ:REGN)  Fairfield Current

Commonwealth of Pennsylvania Public School Empls Retrmt SYS cut its holdings in shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 21.5% ...

Retinal Vein Occlusion Market 2018 Highlights | By Types – Branch Retinal Artery Occlusion, Central Retinal Vein Occlusion | Top 10 Player Analysis by 2023 - Press Release  Digital Journal

Retinal Vein Occlusion Market Information: By Condition (Non-Ischemic and Ischemic), Diagnosis (Optical Coherence Tomography), Treatment and End-User ...

Avastin as effective as Eylea for treating central retinal vein occlusion  National Institutes of Health

Monthly eye injections of Avastin (bevacizumab) are as effective as the more expensive drug Eylea (aflibercept) for the treatment of central retinal vein occlusion ...

Ohr Pharmaceutical Inc (NASDAQ:OHRP) Big Money Sentiment Is 1  Z Tribune

“Big money sentiment for Ohr Pharmaceutical Inc (NASDAQ:OHRP) in Q3 2018 increased to 1, SEC.gov filings reveal. So its up 0.33, from 2018Q2's 0.67.

Clearside Biomedical (CLSD) Sets New 1-Year Low at $1.26  Modern Readers

Clearside Biomedical Inc (NASDAQ:CLSD) reached a new 52-week low on Thursday . The stock traded as low as $1.26 and last traded at $1.33, with a volume ...

Oppenheimer Reiterates $440.00 Price Target for Regeneron Pharmaceuticals (REGN)  Fairfield Current

Oppenheimer set a $440.00 target price on Regeneron Pharmaceuticals (NASDAQ:REGN) in a research report released on Sunday morning. The firm currently ...

Ozurdex for retinal vein occlusion approved in China  Healio

The Chinese Food and Drug Administration has approved Ozurdex to treat adults with macular edema after branch retinal vein occlusion or central retinal vein ...

Regeneron Pharmaceuticals Inc (REGN) Expected to Post Earnings of $5.61 Per Share  Fairfield Current

Equities research analysts expect Regeneron Pharmaceuticals Inc (NASDAQ:REGN) to post earnings per share of $5.61 for the current quarter, according to ...

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) Holdings Reduced by Commonwealth of Pennsylvania Public School Empls Retrmt SYS  Fairfield Current

Commonwealth of Pennsylvania Public School Empls Retrmt SYS lessened its position in shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by ...

Comparison between intravitreal bevacizumab and posterior sub-tenon in | OPTH  Dove Medical Press

Comparison between intravitreal bevacizumab and posterior sub-tenon injection of triamcinolone acetonide in macular edema secondary to retinal vein ...

Head-To-Head Survey: Clearside Biomedical (CLSD) & KemPharm (KMPH)  Fairfield Current

Clearside Biomedical (NASDAQ:CLSD) and KemPharm (NASDAQ:KMPH) are both small-cap medical companies, but which is the superior investment? We will ...

Surgical eye robot performs precision injection in patient with retinal vein occlusion  Medical Xpress

Eye surgeons at University Hospitals Leuven have been the first to use a surgical robot to operate on a patient with retinal vein occlusion. The robot uses a ...

Bevacizumab as effective as aflibercept for central retinal vein occlusion  The Pharmaceutical Journal

Bevacizumab is frequently used off-label for treating macular oedema resulting from central retinal vein occlusion (CRVO), despite a lack of supporting data.

Central Retinal Vein Occlusion (CRVO)  News-Medical.net

Central retinal vein occlusion (CRVO) is the most common disease of the retinal vessels. It refers to a blockage of the vein draining the retinal tissue at the back ...

Ohr Pharmaceutical Inc (NASDAQ:OHRP) Stock Sentiment Dropped to 0.67  The EN Bulletin

“Big money sentiment for Ohr Pharmaceutical Inc (NASDAQ:OHRP) in 2018 Q2 decreased to 0.67, SEC.gov filings reveal. That's down -0.15, from 2018Q1's ...

Disorganization of Retinal Inner Layers Linked to Visual Acuity Prognoses  MD Magazine

A new study suggests patients with disorganized retinal inner layers see lesser levels of visual acuity improvement after therapy.

Surgical robot successfully removes blood clot in patient with retinal vein occlusion  Healio

Blockage from a blood clot causing retinal vein occlusion in a patient was for the first time removed with the help of a surgical robot at the University Hospitals ...

Steven Yeh, MD: The Promise of Suprachoroidal Injections  MD Magazine

At the 36th annual meeting of the American Society of Retinal Specialists (ASRS) in Vancouver, British Columbia, MD Magazine® sat with Steven Yeh, MD, the ...

Biosimilar Ranibizumab Effective in Treating RVO in a Real-World Setting  The Center for Biosimilars

In India, Razumab, manufactured by Intas Pharmaceuticals, was approved as a similar biologic to ranibizumab in 2015; the retrospective study RE-ENACT ...

Noninvasive, High-Resolution Functional Macular Imaging in Subjects With Retinal Vein Occlusion  Healio

Ophthalmic Surgery, Lasers and Imaging Retina | BACKGROUND AND OBJECTIVES:Several imaging modalities have been developed to characterize ...

Branch retinal vein occlusion (BRVO) recovery: Causes, symptoms, and treatment  Bel Marra Health

Branch retinal vein occlusion or BRVO is often referred to as an “eye stroke” and can impact a person's ability to see. The degree of vision loss varies in each ...

Victrex PLC (LON:VCT) Was Downgraded by Berenberg; Allergan Plc Ordinary Shares (AGN) Shorts Increased By 25.7%  The FinExaminer

Berenberg cut Victrex PLC (LON:VCT)'s stock to a Hold rating. The ratings change was issued in a an analyst note today. The financial firm currently has a GBX ...

EYLEA® (aflibercept) Injection Improves Diabetic Retinopathy and Reduces Vision-Threatening Complications in Phase 3 Trial  BioSpace

TARRYTOWN, N.Y., Oct. 25, 2018 /PRNewswire/ --. First trial in non-proliferative diabetic retinopathy to show both a reduction in vision-threatening ...

Central retinal vein occlusion (CRVO): Types, causes, symptoms, and treatment  Bel Marra Health

Central retinal vein occlusion (CRVO) refers to a medical condition of the eye where main vein of the retina has become blocked.

Insider Buying: Clearside Biomedical Inc (CLSD) Director Purchases $10,880.00 in Stock  Fairfield Current

Clearside Biomedical Inc (NASDAQ:CLSD) Director Clay Thorp acquired 8000 shares of the stock in a transaction on Thursday, December 6th. The shares were ...

High systolic BP affects your retina and may lead to complete vision loss  Economic Times

Constant fluctuations in the systolic pressure can lead to many major eye complications.

FEMTOprint develops glass-based puncture tool for retinal vein cannulation  Industrial Laser Solutions Magazine

A collaboration in Switzerland has developed a challenging passive compliant tool for retinal vein occlusion (RVO).

Switching to Aflibercept Demonstrates Improvement in VA, CST for Poor Responders to Bevacizumab in SCORE2  MD Magazine

Those who were switched to aflibercept improved 9 letters of VA, and 110 µm in CST from months 6 to 12.

Altris.AI – The New Era of Retinal Diagnosis is Coming  Business Wire

Altris.AI (Altris, Inc) announced it has signed an agreement with a South Korean ophthalmic and optical medical equipment manufacturer Huvitz Co., Ltd.

Ozurdex® (dexamethasone 0.7mg) now available for millions of patients in China with macular edema secondary to retinal vein occlusion  Markets Insider

--An estimated 7.4 million people in China are living with this sight-threatening conditioni,ii,iii --. DUBLIN, March 22, 2018 /PRNewswire/ -- Today, Allergan plc ...

Eylea Competition Coming But Pipeline Could Maintain Growth For Regeneron  Seeking Alpha

Eylea represents a significant portion of revenue and will face upcoming competition, which could slow Regeneron sales growth over the coming years.

Anti-VEGF Therapy Before Steroids for Retinal Vein Occlusion  Medscape

NICE, France — Aflibercept and ranibizumab are safer than dexamethasone intravitreal implants for the treatment of central retinal vein occlusion, a new study ...

Heartland Advisors Has Trimmed Its Portland General Electric Company (POR) Position; Shorts at Ohr Pharmaceutical (OHRP) Lowered By 5.19%  The FinExaminer

Heartland Advisors Inc decreased Portland General Electric Company (POR) stake by 6.2% reported in 2018Q3 SEC filing. Heartland Advisors Inc sold 15972 ...

Short Interest in Clearside Biomedical Inc (NASDAQ:CLSD) Declines By 37.6%  Fairfield Current

Clearside Biomedical Inc (NASDAQ:CLSD) was the recipient of a significant drop in short interest in the month of November. As of November 15th, there was ...

Putnam FL Investment Management Co. Boosts Holdings in Regeneron Pharmaceuticals Inc (NASDAQ:REGN)  PressOracle

Putnam FL Investment Management Co. raised its stake in shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 1.6% in the 3rd quarter, according to ...

Placenta Growth Factor Market 2018: Future Trends, Key Players: 123, Alteogen Inc., Chengdu Kanghong Pharmaceuticals Group Co Ltd, Clearside BioMedical, Inc., Formycon AG, Regeneron Pharmaceuticals Inc, ThromboGenics NV and more…  Industry Journal

Industrial Forecast on Placenta Growth Factor Market: A new report titled, “Global Placenta Growth Factor Market”, has been added by Reports Monitor to its vast ...

Retinal Vein Occlusion Associated With Stroke  Medscape

Retinal vein occlusion (RVO) is significantly associated with stroke development, according to a recent study. Although the investigators adjusted for potential ...

Biosimilars Reported Safe, Effective for Retinal Disease  Medscape

CHICAGO — Biosimilars made in India are as safe and effective for retinal vascular diseases as the American-made originator drugs, but cost about 40% less, ...

Complications After Intravitreal Injection Aggravate  Medscape

VANCOUVER, Canada — Clusters of inflammatory responses after intravitreal injections have unnerved some specialists, who will share their experiences and ...

Contrasting Clearside Biomedical (CLSD) & KemPharm (KMPH)  PressOracle

Clearside Biomedical (NASDAQ:CLSD) and KemPharm (NASDAQ:KMPH) are both small-cap medical companies, but which is the better stock? We will ...

Q2 2018 Sentiment for Charming Shoppes Inc (NASDAQ:CHRS) at 2.28  Z Tribune

“Big money sentiment for Charming Shoppes Inc (NASDAQ:CHRS) in 2018 Q2 increased to 2.28, revealed SEC filings. So its up 0.79, from 2018Q1's 1.49.

Case Report Highlights Acute Central Retinal Vein Occlusion in Scleroderma Patient  Scleroderma News

Researchers in Saudi Arabia at King Fahd Hospital of the University and the University of Dammam reported a case of a male patient with scleroderma who was ...

Safety, Tolerability Increases Post-Bevacizumab Injection in Intraocular Pressure  MD Magazine

New research has shown that increased IOP is tolerable to corneal endothelium, and safe for most patients' eyes despite immediate increases post-injection.

Biosimilars for bevacizumab and ranibizumab show promise for retinal diseases  Healio

VANCOUVER, British Columbia — Data for two new biosimilars for ranibizumab and bevacizumab, currently available in India, show the treatments are safe and ...

of Dec 10, 2018 Clearside Biomedical Inc (NASDAQ:CLSD) Sellers Decreased Their Shorts By 22.8%  The EN Bulletin

It was noted a decrease on Clearside Biomedical Inc (NASDAQ:CLSD)'s short interest with 22.8%. FINRA issued in December CLSD's total 867000 short ...

Clearside Biomedical Inc (CLSD) Given Average Recommendation of “Hold” by Brokerages  Fairfield Current

Shares of Clearside Biomedical Inc (NASDAQ:CLSD) have received a consensus rating of “Hold” from the eleven research firms that are covering the firm, ...

Retinal Vein Occlusion Therapeutics Market Share Worldwide Industry Growth, Size, Statistics, Opportunities & Forecasts up to 2023  News by Sharp Reports

An analysis of Retinal Vein Occlusion Therapeutics market has been provided in the latest report launched by Market Study Report that primarily focuses on the ...

SCORE2: Visual acuity results with bevacizumab non-inferior to aflibercept as treatment for macular edema due to CRVO  Healio

The SCORE2 study showed that intravitreal bevacizumab is non-inferior to aflibercept as a treatment for macular edema due to central retinal or hemiretinal vein ...

Saving the sight of millions  Medical Xpress

Two eye surgeons (ophthalmologists) have written a first-of-its-kind book to save the sight of millions of patients around the world by making eye injections ...

Regeneron's Eylea Stumbles as FDA Issues CRL for New Dosing Label  BioSpace

Tarrytown, N.Y.-based Regeneron received some unwelcome news. The U.S. Food and Drug Administration (FDA) rejected the company's attempt to secure a ...

Placenta Growth Factor Market Trends Analysis, Top Manufacturers, Shares, Growth  AlgosOnline

Global Placenta Growth Factor Market Forecast to 2025 released By Market Study Report provides Market information about industry Top Key Players, Countries ...

Ohr Pharmaceutical Inc's (NASDAQ:OHRP) Sentiment is 0.67  Thorold News

Ohr Pharmaceutical Inc (NASDAQ:OHRP) institutional sentiment decreased to 0.67 in Q2 2018. Its down -0.15, from 0.82 in 2018Q1. The ratio has dropped, as 6 ...

Stocks to Keep Your Eyes on: Clearside Biomedical, Inc. (NASDAQ:CLSD), HSBC Holdings plc (NYSE:HSBC)  The Newburgh Press

Clearside Biomedical, Inc. (NASDAQ:CLSD) Clearside Biomedical, Inc. is a biopharmaceutical company is engaged in developing first-in-class drug therapies ...

Clearside Biomedical: Buy Or Sell Before 2018 Catalysts  Seeking Alpha

The 8-week data from the first phase 3 trial (SAPPHIRE) in treating macular edema due to retinal vein occlusion is expected in Q4 (a big binary event for the st.

» Load more